IL129824A - Pharmaceutical compositions comprising 2-amino-1,3-propanediol derivatives for preventing and/or treating chronic rejection in a recipient for organ or tissue allo- or xenotransplants - Google Patents

Pharmaceutical compositions comprising 2-amino-1,3-propanediol derivatives for preventing and/or treating chronic rejection in a recipient for organ or tissue allo- or xenotransplants

Info

Publication number
IL129824A
IL129824A IL12982497A IL12982497A IL129824A IL 129824 A IL129824 A IL 129824A IL 12982497 A IL12982497 A IL 12982497A IL 12982497 A IL12982497 A IL 12982497A IL 129824 A IL129824 A IL 129824A
Authority
IL
Israel
Prior art keywords
xenotransplants
recipient
organ
amino
preventing
Prior art date
Application number
IL12982497A
Other languages
English (en)
Other versions
IL129824A0 (en
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to IL14709997A priority Critical patent/IL147099A0/xx
Publication of IL129824A0 publication Critical patent/IL129824A0/xx
Publication of IL129824A publication Critical patent/IL129824A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Light Receiving Elements (AREA)
IL12982497A 1996-11-19 1997-11-17 Pharmaceutical compositions comprising 2-amino-1,3-propanediol derivatives for preventing and/or treating chronic rejection in a recipient for organ or tissue allo- or xenotransplants IL129824A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL14709997A IL147099A0 (en) 1996-11-19 1997-11-17 New use for 1,3-propanediol derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9624038.7A GB9624038D0 (en) 1996-11-19 1996-11-19 Organic compounds
PCT/EP1997/006408 WO1998022100A2 (en) 1996-11-19 1997-11-17 New use for 1,3-propanediol derivatives

Publications (2)

Publication Number Publication Date
IL129824A0 IL129824A0 (en) 2000-02-29
IL129824A true IL129824A (en) 2003-07-31

Family

ID=10803173

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12982497A IL129824A (en) 1996-11-19 1997-11-17 Pharmaceutical compositions comprising 2-amino-1,3-propanediol derivatives for preventing and/or treating chronic rejection in a recipient for organ or tissue allo- or xenotransplants

Country Status (25)

Country Link
US (3) US6274629B1 (es)
EP (2) EP1312359B1 (es)
JP (2) JP4004070B2 (es)
CN (2) CN1293876C (es)
AT (2) ATE275947T1 (es)
AU (1) AU728420B2 (es)
BR (1) BR9713105A (es)
CA (1) CA2270952C (es)
CZ (1) CZ174999A3 (es)
DE (2) DE69738033T2 (es)
DK (1) DK1312359T3 (es)
ES (2) ES2289041T3 (es)
GB (1) GB9624038D0 (es)
HK (1) HK1022639A1 (es)
HU (1) HUP0000343A3 (es)
ID (1) ID21568A (es)
IL (1) IL129824A (es)
NO (1) NO992259D0 (es)
NZ (1) NZ335629A (es)
PL (1) PL190348B1 (es)
PT (2) PT941082E (es)
RU (1) RU2217136C2 (es)
SI (1) SI1312359T1 (es)
SK (1) SK284806B6 (es)
WO (1) WO1998022100A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1457478B1 (en) 1998-11-11 2017-07-19 Novartis AG Production of 2-amino-2-[2-(4-alkyl-phenyl)ethyl]propane-1,3-diols
SK8332002A3 (en) * 1999-12-16 2003-04-01 Teva Pharma Novel processes for making- and a new crystalline form of leflunomide
AU8533101A (en) 2000-08-31 2002-03-13 Merck & Co Inc Phosphate derivatives as immunoregulatory agents
WO2002067915A1 (en) * 2001-02-22 2002-09-06 Novartis Ag Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function
MXPA03009586A (es) * 2001-04-20 2004-05-24 Debiopharm Sa Ciclosporina modificada que puede ser usada como un pro-farmaco y uso de la misma.
WO2002100148A2 (en) * 2001-06-08 2002-12-19 Novartis Ag Treatment or prophylaxis of insulin-producing cell graft rejection
GB0117921D0 (en) * 2001-07-23 2001-09-12 Novartis Ag Organic compounds
US20040136972A1 (en) * 2001-09-07 2004-07-15 Yeda Research And Development Co. Ltd. Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
US7780993B2 (en) * 2001-09-07 2010-08-24 Yeda Research And Development Co. Ltd. Therapeutic transplantation using developing, human or porcine, renal or hepatic, grafts
GB0125443D0 (en) * 2001-10-23 2001-12-12 Novartis Ag Organic Compounds
KR20080035702A (ko) 2002-01-11 2008-04-23 상꾜 가부시키가이샤 아미노 알코올 유도체 또는 포스폰산 유도체 및 이들을함유하는 의약 조성물
GB0217777D0 (en) * 2002-07-31 2002-09-11 Novartis Ag Organic compounds
IL165425A0 (en) * 2004-11-28 2006-01-15 Yeda Res & Dev Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
KR20110005320A (ko) 2003-04-08 2011-01-17 노파르티스 아게 Ｓ1ｐ 수용체 아고니스트 및 당 알콜을 포함하는 고형 제약 조성물
US7524887B2 (en) 2003-06-06 2009-04-28 Sanofi-Aventis Deutschland Gmbh 2-amino-1,3-propanediol compounds for the treatment of acute pain
EP1484057A1 (en) * 2003-06-06 2004-12-08 Aventis Pharma Deutschland GmbH Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain
CA2778309C (en) * 2003-06-24 2014-12-02 University Of Connecticut Methods of inhibiting vascular permeability and apoptosis
US7074659B2 (en) * 2003-11-13 2006-07-11 Volterra Semiconductor Corporation Method of fabricating a lateral double-diffused MOSFET (LDMOS) transistor
JP2005272453A (ja) 2004-02-24 2005-10-06 Sankyo Co Ltd アミノアルコール化合物
PL1773307T3 (pl) * 2004-07-30 2015-03-31 Novartis Ag Preparaty 2-amino-1,3-propanodioli i ich analogów
ES2369520T3 (es) 2005-12-15 2011-12-01 Mitsubishi Tanabe Pharma Corporation Compuesto amínico y su uso para propósitos médicos.
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
RU2496486C1 (ru) 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
RU2663833C2 (ru) * 2013-03-05 2018-08-10 Биокон Лимитед Способ получения соединений 2-амино-1,3-пропандиола и их солей
EP3143991B1 (en) 2015-09-18 2020-04-08 Sanovel Ilac Sanayi ve Ticaret A.S. Fingolimod capsule composition
JP2024521882A (ja) * 2021-05-31 2024-06-04 上海雲晟研新生物科技有限公司 フィンゴリモド薬用塩、製造方法、それを含む医薬組成物及び使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3904679A (en) * 1972-05-23 1975-09-09 Upjohn Co 15-Methyl and 15-ethyl prostaglandin F{HD 2{331 {0 {B analogs
ES2196002T3 (es) * 1991-07-25 2003-12-16 Idec Pharma Corp Anticuerpos recombinantes para terapia humana.
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
EP0627406B1 (en) * 1992-10-21 1998-10-28 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
ES2230571T3 (es) * 1995-12-28 2005-05-01 Mitsubishi Pharma Corporation `composicion farmaceutica destinada para la administracion topica que comprende el 2-amino-2-(2-(4-octilfenil)etil) propan-1,3-diol para el tratamiento de las enfermedades causadas por una alteracion inmunitaria.
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
AU735406B2 (en) * 1997-02-27 2001-07-05 Novartis Ag Pharmaceutical composition

Also Published As

Publication number Publication date
EP1312359A2 (en) 2003-05-21
DK1312359T3 (da) 2007-10-08
AU5483198A (en) 1998-06-10
AU728420B2 (en) 2001-01-11
ATE369846T1 (de) 2007-09-15
WO1998022100A3 (en) 1998-06-25
NZ335629A (en) 2001-09-28
CN1515253A (zh) 2004-07-28
GB9624038D0 (en) 1997-01-08
CA2270952A1 (en) 1998-05-28
PL333463A1 (en) 1999-12-20
DE69738033D1 (de) 2007-09-27
SK284806B6 (sk) 2005-11-03
CN1293876C (zh) 2007-01-10
RU2217136C2 (ru) 2003-11-27
JP4004070B2 (ja) 2007-11-07
US20030069315A1 (en) 2003-04-10
HUP0000343A3 (en) 2001-06-28
EP0941082A2 (en) 1999-09-15
US6486209B2 (en) 2002-11-26
ES2227726T3 (es) 2005-04-01
JP2004256554A (ja) 2004-09-16
IL129824A0 (en) 2000-02-29
EP0941082B1 (en) 2004-09-15
SK65999A3 (en) 1999-12-10
DE69738033T2 (de) 2008-04-30
PT1312359E (pt) 2007-11-09
HK1022639A1 (en) 2000-08-18
ATE275947T1 (de) 2004-10-15
JP2001503780A (ja) 2001-03-21
PT941082E (pt) 2004-12-31
HUP0000343A2 (hu) 2000-12-28
EP1312359B1 (en) 2007-08-15
CN1146411C (zh) 2004-04-21
SI1312359T1 (sl) 2008-08-31
DE69730727D1 (de) 2004-10-21
PL190348B1 (pl) 2005-11-30
CA2270952C (en) 2007-09-18
BR9713105A (pt) 2000-04-11
NO992259L (no) 1999-05-10
ES2289041T3 (es) 2008-02-01
CN1237906A (zh) 1999-12-08
CZ174999A3 (cs) 1999-08-11
US20010056124A1 (en) 2001-12-27
ID21568A (id) 1999-06-24
US6274629B1 (en) 2001-08-14
WO1998022100A2 (en) 1998-05-28
DE69730727T2 (de) 2005-09-22
NO992259D0 (no) 1999-05-10
EP1312359A3 (en) 2004-01-02

Similar Documents

Publication Publication Date Title
IL129824A (en) Pharmaceutical compositions comprising 2-amino-1,3-propanediol derivatives for preventing and/or treating chronic rejection in a recipient for organ or tissue allo- or xenotransplants
ATE232531T1 (de) Heterobizyklische derivate
DE69415445D1 (de) Zytotoxische Stilben-Derivate und diese enthaltende pharmazeutische Zusammensetzungen
MY136674A (en) Novel quinuclidine carbamate derivatives and medicinal compositions containing the same
MY118904A (en) 4-oxo-1, 4-dihydro-3-quinolinecarboxamides as antiviral agents
ZA9110166B (en) 1,4-benzothiazepine derivatives
KR900016098A (ko) 카페인산의 유도체 및 이를 함유하는 약제학적 조성물
NZ230503A (en) Substituted beta-diketones and pharmaceutical compositions
ATE115572T1 (de) N-2-chlorbenzyl-2-oxo- und n-2-chlorbenzyl-2,2,- dioxo-1,2,3-oxathiazolidinderivate, ihre herstellung und ihre verwendung in der synthese von thieno(3,2-c>pyridinderivaten.
ES2059685T3 (es) Acilaminoalquilpiridinamidas inhibidoras de metastasis tumoral.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees